IP Library Granted Patent US 8,664,204
Granted Patent B2
US 8,664,204 · App. 13/941,261 · Granted Mar 4, 2014

Phosphoramidate alkylator prodrugs

Inventors: Mark Matteucci (Portola Valley, CA); Jian-Xin Duan (South San Francisco, CA); Hailong Jiao (Foster City, CA)
Assignee: Threshold Pharmaceuticals, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,664,204
App. No.
13/941,261
Granted
Mar 4, 2014
Kind
B2
Abstract

Phosphoramidate alkylator prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.

Claims (13)

1. A method to synthesize a compound having formula I:

or a pharmaceutically acceptable salt thereof; wherein each X 4 is halo; and T is:

comprising reacting a compound having the formula T-OH, a tri-substituted phosphine, a compound of the formula

and a dialkyl azodicarboxylate to yield the compound of formula I.

2. The method of claim 1 , wherein X 4 is chloro.

3. The method of claim 2 , wherein X 4 is bromo.

4. The method of claim 3 , wherein the compound of the formula:

is made by reacting bromoethylammonium bromide, phosphoryl chloride and triethyl amine.

5. The method of any one of the preceding claims, wherein each substituent in 2 the trisubstituted phosphine is independently selected from [H], C 1 -C 6 alkyl, C 1 -C 6 heteroalkyl, C 3 -C 8 cycloalkyl, heterocyclyl, aryl, heteroaryl, and C 1 -C 6 alkoxy.

6. The method of claim 5 , wherein the trisubstituted phosphine is selected from the group consisting of triphenylphosphine, tributylphosphine, tripropylphosphine, triethylphosphine, trimethylphosphine and tributylphosphite.

7. The method of claim 5 , wherein the trisubstituted phosphine is triphenylphosphine.

8. The method of claim 1 , wherein the dialkyl azodicarboxylate is diethyl or diisopropyl azodicarboxylate.

9. The method of claim 8 , wherein the dialkyl azodicarboxylate is diisopropyl azodicarboxylate.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 26, 2022
From: MOLECULAR TEMPLATES, INC.
To: IMMUNOGENESIS, INC.
Reel/Frame 061545/0067 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 2, 2021
From: MOLECULAR TEMPLATES, INC.
To: IMMUNOGENESIS, INC.
Reel/Frame 056414/0241 →
RELEASE OF SECURITY INTEREST Recorded May 22, 2020
From: PERCEPTIVE CREDIT HOLDINGS II, LP
To: MOLECULAR TEMPLATES OPCO, INC.
Reel/Frame 052733/0890 →
CHANGE OF NAME AND ADDRESS Recorded Oct 12, 2018
From: THRESHOLD PHARMACEUTICALS, INC.
To: MOLECULAR TEMPLATES, INC.
Reel/Frame 048404/0347 →
SECURITY AGREEMENT Recorded Feb 28, 2018
From: MOLECULAR TEMPLATES OPCO, INC.; MOLECULAR TEMPLATES, INC.
To: PERCEPTIVE CREDIT HOLDINGS II, LP
Reel/Frame 045466/0472 →
Continuity (4)
Continuation 13163303 · Jun 17, 2011
Continuation 11993822
Provisional Application 60695755 · Jun 29, 2005
Related Publication 20130303778A1 · Nov 14, 2013